Daniel Watkins

Daniel Watkins General Information

Description

Dr. Daniel Watkins serves as Investment Committee Member at N.XT. He serves as Chief Executive Officer at Pelagos Pharmaceuticals. He is the Co- Founder & serves as Director at Mercury Data Science. He serves as a Board Member at ESG Solutions. He is also a Co-Founder and serves as Venture Partner at Mercury Fund. He also serves as Board Member at Ripple Science. He serves as Board Member at Resonant Therapeutics and Sinopsys Surgical. He served as Board Member at Benson Hill. He focuses on startups utilizing software, cloud computing, and/or machine learning to drive the next wave of scientific innovation in healthcare, agriculture, and other industrial markets. He currently serves on the boards of Mercury portfolio companies Benson Hill, Clean Chemistry, Deep Imaging, DNAtrix, Resonant, Sinopsys, and Swift Biosciences. His previous investments at Mercury have included Crate Health (acq. by SCI Solutions). Before co-founding Mercury, he served in several operational roles including CEO of DNAtrix and Nanospectra Biosciences, both startup oncology companies. Previously, He was Vice President at a boutique investment banking firm and Worldwide Manager of Operations and Control Systems for Scientific Software-Intercomp (Baker Hughes).He received his B.S. from Rice University and his M.S. and Ph.D. from Carnegie Mellon University, all in Materials Science. He is also a co-founder of the Rice Alliance for Technology and Entrepreneurship at Rice University. Outside of Mercury, he serves on the advisory boards of Northwestern University's Innovation and New Ventures Office (INVO), the Rice Alliance, the University of Michigan's Venture Center Council, and the University of Illinois Proof of Concept Fund Committee. He also serves as Board Member at Ambyint.